| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
General Counsel
1 company
Kelley Shannon T is a General Counsel at MDGL. Recent filings cover 0 purchases and 14 sales. Those positions are worth an estimated $5.9M at current prices.
Our model assigns Kelley Shannon T a below-average insider score of 24/100, based on 3 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -53.3%.
Kelley Shannon T's largest disclosed position is in MDGL as General Counsel, worth about $5.9M. The recent filings there lean toward selling, a net 3,712 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | MDGL Madrigal Pharmaceuticals, Inc. | General Counsel | Sell | 664 | $514.97 | $341,940.08 | -5.5% | - | - | |
| Mar 6, 2026 | MDGL Madrigal Pharmaceuticals, Inc. | General Counsel | Sell | 360 | $431.94 | $155,498.40 | -2.9% | +13.7% | - | |
| Jan 20, 2026 | MDGL Madrigal Pharmaceuticals, Inc. | General Counsel | Sell10b5-1 | 692 | $497.36 | $344,173.11 | -7.5% | +4.4% | - | |
| Aug 18, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | General Counsel | Sell10b5-1 | 1,304 | $367.81 | $479,626.86 | -12.4% | +41.4% | +34.0% | |
| Mar 3, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | General Counsel | Sell10b5-1 | 415 | $335.00 | $139,025.00 | -5.4% | -13.0% | +35.9% | |
| Jan 17, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | General Counsel | Sell | 277 | $273.41 | $75,734.57 | -3.5% | +2.7% | +70.8% |